ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total transaction of $1,316,000.00. Following the sale, the insider now owns 1,148,499 shares of the company’s stock, valued at approximately $15,114,246.84. This represents a 8.01 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Sarina Tanimoto also recently made the following trade(s):
- On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $14.88, for a total transaction of $1,488,000.00.
ARS Pharmaceuticals Stock Up 3.0 %
ARS Pharmaceuticals stock opened at $12.64 on Friday. ARS Pharmaceuticals, Inc. has a twelve month low of $5.02 and a twelve month high of $18.51. The company has a 50 day moving average of $14.67 and a 200-day moving average of $12.32. The stock has a market capitalization of $1.23 billion, a PE ratio of -24.78 and a beta of 0.88.
Institutional Trading of ARS Pharmaceuticals
Analyst Ratings Changes
SPRY has been the subject of a number of analyst reports. Leerink Partners lifted their price objective on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, September 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 price objective on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Finally, William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $24.00.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Read More
- Five stocks we like better than ARS Pharmaceuticals
- The Risks of Owning Bonds
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- What Are Growth Stocks and Investing in Them
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- How to Use the MarketBeat Excel Dividend Calculator
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.